{"database": "lobbying", "table": "lobbying_activities", "rows": [[2018986, "802352db-c6d1-423c-894c-95109fca8074", "3T", "KNIGHT CAPITOL CONSULTANTS", 40036301, "BRAEBURN PHARMACEUTICALS, INC.", 2017, "third_quarter", "HCR", "Controlled Substances Act provisions relating to the distribution of medication assisted therapies (The Protecting Patient Access to Emergency Medications Act, S. 916/H.R. 304.  Adequacy of funding for opioid overuse disorder (OUD) treatment in the Affordable Care Act Repeal/Replace legislation.", "Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE", 30000, null, 0, 1, "2017-09-29T13:33:43.683000-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["2018986"], "units": {}, "query_ms": 0.46922703040763736, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}